Baseline characteristics of allogeneic hematopoietic cell transplantation (N = 360)
| Variable . | Value . | Butyrate group absent (<0.0001) (%) . | Butyrate group low (0.0001-0.01) (%) . | Butyrate group high (>0.01) (%) . | Total (%) . | Fisher P . |
|---|---|---|---|---|---|---|
| Age, y | ≤29 | 14 (53.8) | 12 (46.2) | 0 (0.0) | 26 (100) | .156 |
| 30-39 | 23 (47.9) | 18 (37.5) | 7 (14.6) | 48 (100) | ||
| 40-49 | 19 (35.8) | 24 (45.3) | 10 (18.9) | 53 (100) | ||
| 50-59 | 39 (36.4) | 44 (41.1) | 24 (22.4) | 107 (100) | ||
| ≥60 | 49 (38.9) | 49 (38.9) | 28 (22.2) | 126 (100) | ||
| Sex | Female | 58 (44.3) | 57 (43.5) | 16 (12.2) | 131 (100) | .035 |
| Male | 86 (37.6) | 90 (39.3) | 53 (23.1) | 229 (100) | ||
| Underlying disease | Leukemia | 90 (48.1) | 69 (36.9) | 28 (15.0) | 187 (100) | .052 |
| Lymphoma | 20 (30.3) | 28 (42.4) | 18 (27.3) | 66 (100) | ||
| Multiple myeloma | 13 (36.1) | 14 (38.9) | 9 (25.0) | 36 (100) | ||
| Myelodysplastic syndrome | 18 (31.0) | 30 (51.7) | 10 (17.2) | 58 (100) | ||
| Other disorders | 3 (23.1) | 6 (46.2) | 4 (30.8) | 13 (100) | ||
| Conditioning intensity | Myeloablative | 63 (36.2) | 83 (47.7) | 28 (16.1) | 174 (100) | .071 |
| Reduced intensity | 72 (45.3) | 54 (34.0) | 33 (20.8) | 159 (100) | ||
| Nonmyeloablative | 9 (33.3) | 10 (37.0) | 8 (29.6) | 27 (100) | ||
| Stem cell source | Related identical | 32 (33.3) | 42 (43.8) | 22 (22.9) | 96 (100) | |
| Unrelated identical | 56 (40.6) | 51 (37.0) | 31 (22.5) | 138 (100) | ||
| Nonidentical | 18 (34.6) | 27 (51.9) | 7 (13.5) | 52 (100) | ||
| Umbilical cord | 38 (51.4) | 27 (36.5) | 9 (12.2) | 74 (100) | .105 | |
| Time to engraftment | <14 d | 97 (35.9) | 117 (43.3) | 56 (20.7) | 270 (100) | .027 |
| ≥14 d | 47 (52.2) | 30 (33.3) | 13 (14.4) | 90 (100) | ||
| Corticosteroid use | No | 58 (34.5) | 73 (43.5) | 37 (22.0) | 168 (100) | .122 |
| Yes | 86 (44.8) | 74 (38.5) | 32 (16.7) | 192 (100) | ||
| β−Lactam | No | 17 (23.9) | 29 (40.8) | 25 (35.2) | 71 (100) | .000 |
| Yes | 127 (43.9) | 118 (40.8) | 44 (15.2) | 289 (100) | ||
| Fluoroquinolones | No | 28 (45.2) | 19 (30.6) | 15 (24.2) | 62 (100) | .162 |
| Yes | 116 (38.9) | 128 (43.0) | 54 (18.1) | 298 (100) | ||
| Vancomycin (IV) | No | 3 (27.3) | 4 (36.4) | 4 (36.4) | 11 (100) | .399 |
| Yes | 141 (40.4) | 143 (41.0) | 65 (18.6) | 349 (100) | ||
| Metronidazole | No | 106 (35.3) | 129 (43.0) | 65 (21.7) | 300 (100) | .000 |
| Yes | 38 (63.3) | 18 (30.0) | 4 (6.7) | 60 (100) | ||
| Total | 144 (40.0) | 147 (40.8) | 69 (19.2) | 360 (100) |
| Variable . | Value . | Butyrate group absent (<0.0001) (%) . | Butyrate group low (0.0001-0.01) (%) . | Butyrate group high (>0.01) (%) . | Total (%) . | Fisher P . |
|---|---|---|---|---|---|---|
| Age, y | ≤29 | 14 (53.8) | 12 (46.2) | 0 (0.0) | 26 (100) | .156 |
| 30-39 | 23 (47.9) | 18 (37.5) | 7 (14.6) | 48 (100) | ||
| 40-49 | 19 (35.8) | 24 (45.3) | 10 (18.9) | 53 (100) | ||
| 50-59 | 39 (36.4) | 44 (41.1) | 24 (22.4) | 107 (100) | ||
| ≥60 | 49 (38.9) | 49 (38.9) | 28 (22.2) | 126 (100) | ||
| Sex | Female | 58 (44.3) | 57 (43.5) | 16 (12.2) | 131 (100) | .035 |
| Male | 86 (37.6) | 90 (39.3) | 53 (23.1) | 229 (100) | ||
| Underlying disease | Leukemia | 90 (48.1) | 69 (36.9) | 28 (15.0) | 187 (100) | .052 |
| Lymphoma | 20 (30.3) | 28 (42.4) | 18 (27.3) | 66 (100) | ||
| Multiple myeloma | 13 (36.1) | 14 (38.9) | 9 (25.0) | 36 (100) | ||
| Myelodysplastic syndrome | 18 (31.0) | 30 (51.7) | 10 (17.2) | 58 (100) | ||
| Other disorders | 3 (23.1) | 6 (46.2) | 4 (30.8) | 13 (100) | ||
| Conditioning intensity | Myeloablative | 63 (36.2) | 83 (47.7) | 28 (16.1) | 174 (100) | .071 |
| Reduced intensity | 72 (45.3) | 54 (34.0) | 33 (20.8) | 159 (100) | ||
| Nonmyeloablative | 9 (33.3) | 10 (37.0) | 8 (29.6) | 27 (100) | ||
| Stem cell source | Related identical | 32 (33.3) | 42 (43.8) | 22 (22.9) | 96 (100) | |
| Unrelated identical | 56 (40.6) | 51 (37.0) | 31 (22.5) | 138 (100) | ||
| Nonidentical | 18 (34.6) | 27 (51.9) | 7 (13.5) | 52 (100) | ||
| Umbilical cord | 38 (51.4) | 27 (36.5) | 9 (12.2) | 74 (100) | .105 | |
| Time to engraftment | <14 d | 97 (35.9) | 117 (43.3) | 56 (20.7) | 270 (100) | .027 |
| ≥14 d | 47 (52.2) | 30 (33.3) | 13 (14.4) | 90 (100) | ||
| Corticosteroid use | No | 58 (34.5) | 73 (43.5) | 37 (22.0) | 168 (100) | .122 |
| Yes | 86 (44.8) | 74 (38.5) | 32 (16.7) | 192 (100) | ||
| β−Lactam | No | 17 (23.9) | 29 (40.8) | 25 (35.2) | 71 (100) | .000 |
| Yes | 127 (43.9) | 118 (40.8) | 44 (15.2) | 289 (100) | ||
| Fluoroquinolones | No | 28 (45.2) | 19 (30.6) | 15 (24.2) | 62 (100) | .162 |
| Yes | 116 (38.9) | 128 (43.0) | 54 (18.1) | 298 (100) | ||
| Vancomycin (IV) | No | 3 (27.3) | 4 (36.4) | 4 (36.4) | 11 (100) | .399 |
| Yes | 141 (40.4) | 143 (41.0) | 65 (18.6) | 349 (100) | ||
| Metronidazole | No | 106 (35.3) | 129 (43.0) | 65 (21.7) | 300 (100) | .000 |
| Yes | 38 (63.3) | 18 (30.0) | 4 (6.7) | 60 (100) | ||
| Total | 144 (40.0) | 147 (40.8) | 69 (19.2) | 360 (100) |